CUE - Company ID 0001645460
The table below shows Cue Biopharma, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $5.69M | $2.15M | $2.95M | $421.00K | $3.34M | $2.66M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $6.90M | $4.75M | $7.91M | $8.55M | $9.38M | $9.53M |
Cue Biopharma, Inc. reported annual revenue of $27.47M for fiscal year 2025. That is up 195.7% from $9.29M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $1.14M (FY 2018) to $27.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $4.15M |
| $4.94M |
| $3.68M |
| $4.17M |
| $2.87M |
| $3.51M |
| Operating income | -$5.35M | -$7.59M | -$8.63M | -$12.30M | -$8.81M | -$10.38M |
| Income tax | - | - | - | - | - | - |
| Net income | -$5.18M | -$7.45M | -$8.48M | -$12.26M | -$8.66M | -$10.17M |
| EPS (diluted) | -$1.08 | -$0.07 | -$0.09 | -$4.95 | -$0.17 | -$0.20 |